Department of Pharmacology, School of Medicine, Southern University of Science and Technology, Shenzhen 518000, China.
Viruses. 2022 May 15;14(5):1049. doi: 10.3390/v14051049.
Despite the existence of various types of vaccines and the involvement of the world's leading pharmaceutical companies, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains the most challenging health threat in this century. Along with the increased transmissibility, new strains continue to emerge leading to the need for more vaccines that would elicit protectiveness and safety against the new strains of the virus. Nucleic acid vaccines seem to be the most effective approach in case of a sudden outbreak of infection or the emergence of a new strain as it requires less time than any conventional vaccine development. Hence, in the current study, a DNA vaccine encoding the trimeric prefusion-stabilized ectodomain (S1+S2) of SARS-CoV-2 S-protein was designed by introducing six additional prolines mutation, termed HexaPro. The three-dose regimen of designed DNA vaccine immunization in mice demonstrated the generation of protective antibodies.
尽管存在各种类型的疫苗，并且世界领先的制药公司也参与其中，但严重急性呼吸系统综合症冠状病毒 2 型（SARS-CoV-2）仍然是本世纪最具挑战性的健康威胁。随着传染性的增加，新的毒株不断出现，需要更多的疫苗来针对病毒的新毒株产生保护作用和安全性。在感染突然爆发或出现新毒株的情况下，核酸疫苗似乎是最有效的方法，因为它比任何传统疫苗的开发都需要更少的时间。因此，在当前的研究中，设计了一种编码 SARS-CoV-2 S 蛋白三聚体预融合稳定的外域（S1+S2）的 DNA 疫苗，该疫苗通过引入六个额外的脯氨酸突变，称为 HexaPro。在小鼠中进行的三剂设计 DNA 疫苗免疫方案显示产生了保护性抗体。
